Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, recently announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has established coverage of the StrataNGSTM test for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/ or metastatic solid tumors.